Tom Mathers


Tom joined Pappas Capital in 2018, bringing with him more than 26 years of executive management experience in the life sciences and medical device industries. Based in Boston, Tom is responsible for new company formation, as well as sourcing and evaluating prospective investment opportunities, and providing expertise and oversight to Pappas portfolio companies.

Tom previously served as CEO of CoLucid Pharmaceuticals (NASDAQ: CLCD), a Pappas Capital portfolio company that was acquired in 2017 by Eli Lilly & Company for nearly $1 billion. Prior to CoLucid, Tom served as President and CEO of Peptimmune, Inc.; President and CEO of Cell Based Delivery, Inc.; Vice President and General Manager of Cardion AG; and Vice President of Strategic Development at Genzyme.

Tom currently serves as a board observer for 4D Molecular Therapeutics, and as a trustee of Butler University. Tom previously served on the Board of Directors for the Biotechnology Industry Organization for nine years, where he was active in the policy areas of capital formation, bioethics, intellectual property and regulatory policy. From 1988 to 1991, he served as a captain in the United States Army and was awarded several medals for his services as an AH-64 Apache helicopter pilot in the Gulf War. Tom holds several patents and patents pending.


United States Military Academy at West Point (BS in Engineering)

Serves as an Observer for: